LILRB1通过CREB-SORBS3通路增强了扩散型大B细胞淋巴瘤的进展
Liyuan Cao1, Hanqing Zhao2, Xuanyi Zhou1
1Hongqiao International Institute of Medicine, Shanghai Tongren Hospital, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Faculty of Basic Medicine, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai, 200025, China.
白细胞免疫球蛋白样受体B1 (LILRB1) 在扩散性大B细胞淋巴瘤 (DLBCL) 中高度表达,并促进癌细胞生长. 准LILRB1可能为治疗对当前疗法的耐药性DLBCL患者提供新的策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 在耐标准化疗和免疫治疗的患者中对有效治疗有着重大未满足的需求.
- 确定新的治疗点对于改善DLBCL的结果至关重要.
研究的目的:
- 调查白细胞免疫球蛋白样受体B1 (LILRB1) 在DLBCL病变发生中的作用.
- 探索LILRB1影响DLBCL细胞增殖和生存的潜在分子机制.
主要方法:
- 对临床患者数据库的分析,以评估LILRB1表达及其与患者存活率的相关性.
- 在体外和体内功能研究中,使用短毛RNA (shRNA) 来击败LILRB1.1.
- RNA测序 (RNA-seq),西部污染和染色体免疫沉 (ChIP) 以阐明信号通路.
主要成果:
- 在DLBCL细胞中,LILRB1的表达很高,并且与较差的整体存活率有关.
- 抑制LILRB1显著抑制DLBCL细胞的增殖,无论是体外还是体内.
- LILRB1上调CREB酸化和SORBS3表达,促进DLBCL细胞的增殖和瘤性.
结论:
- 通过LILRB1-CREB-SORBS3通路,LILRB1在维持DLBCL细胞增殖和瘤性方面发挥着至关重要的作用.
- LILRB1代表了DLBCL治疗的有前途的治疗标,特别是对于治疗耐药性的患者.
更多相关视频
10:16SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry
Published on: January 6, 2017
07:23Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome
Published on: June 15, 2016
相关概念视频
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Negative Regulator Molecules
PI3K/mTOR/AKT Signaling Pathway
MAPK Signaling Cascades
